# US 2022/0025377 A1 · Products and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025377 A1
- Document ID: US20220025377A1
- Status: Published application
- Kind: A1
- Application number: 17/450,064
- Filed: 2021-10-05
- Published: 2022-01-27
- Earliest claimed: 2017-04-05
- Assignees: Silence Therapeutics GmbH
- Applicants: Silence Therapeutics GMBH
- Inventors: Sibylle DAMES; Ute Schaeper; Judith Hauptmann; Christian Frauendorf; Lucas Bethge; Adrien Weingärtner
- Web page: https://patentgrep.com/patent/US20220025377A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/56: the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- C12Y 304/21: Serine endopeptidases (3.4.21)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/351: Conjugate
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as β-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.

## Claims

### Claim 1

A nucleic acid for inhibiting expression of TMPRSS6, comprising at least one duplex region that comprises at least a portion of a first strand and at least a portion of a second strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from the TMPRSS6 gene, wherein said nucleic acid comprises the following first strand:
5′-3′: aaccagaagaagcagguga;
optionally wherein the nucleic further comprises the following second strand:
5′-3′: ucaccugcuucuucugguu

### Claim 2

A nucleic acid according to any preceding claim, wherein one or more nucleotides on the first and/or second strand are modified, to form modified nucleotides.

### Claim 3 (depends on 2)

A nucleic acid of claim 2, wherein said first strand comprises a nucleotide sequence of SEQ ID NO:17, and wherein said second strand comprises the nucleotide sequence of SEQ ID NO:18.
SEQ ID
5′aaccagaaga
6273646282647284546
NO: 17
agcagguga 3′
SEQ ID
5′ucaccugcuu
1727354715351718451
NO: 18
cuucugguu 3′
wherein the specific modifications are depicted by the following numbers
1=2′F-dU,
2=2′F-dA,
3-2′F-dC,
4=2′F-dG,
5=2′-OMe-rU;
6=2′-OMe-rA;
7=2′-OMe-rC;
8-2′-OMe-rG.

### Claim 4

A nucleic acid according to any preceeding claim conjugated to a ligand, optionally at the 5′ end of the second strand.

### Claim 5 (depends on 4)

A nucleic acid according to claim 4 wherein the ligand comprises (i) one or more N-acetyl galactosamine (GalNAc) moieties and derivatives thereof, and (ii) a linker, wherein the linker conjugates the GalNAc moieties to the nucleic acid.

### Claim 6 (depends on 4, 5)

A nucleic acid according to claim 4 or 5, wherein linker is a bivalent or trivalent or tetravalent branched structure.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A conjugated nucleic acid according to any of claims 4-6, having the structure:
wherein Z is a nucleic acid according to any of claims 1 to 40.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A nucleic acid according to any one of claims 1 to 6, or a conjugated nucleic according to claim 7, wherein the nucleic acid is stabilised at the 5′ and/or 3′ end of either or both strands.

### Claim 9 (depends on 8)

A nucleic acid according to claim 8 comprising a phosphorothioate linkage between the terminal one, two or three 3′ nucleotides and/or 5′ nucleotides of the first and/or the second strand,
or comprising
a phosphorodithioate linkage.

### Claim 10 (depends on 9)

A nucleic acid according to claim 9 comprising two phosphorothioate linkage between each of the three terminal 3′ and between each of the three terminal 5′ nucleotides on the first strand, and two phosphorothioate linkages between the three terminal nucleotides of the 3′ end of the second strand, having the structure
5′-3′
TMPRSS6-
6 (ps) 2 (ps) 736462826472845 (ps) 4 (ps) 6
hcm-9A
5′-3′
TMPRSS6-
17273547153517184 (ps) 5 (ps) 1
hcm-9B

### Claim 11

A composition comprising a nucleic acid or conjugated nucleic acid of any preceding claim and a physiologically acceptable excipient.

### Claim 12

A nucleic acid or conjugated nucleic acid or composition according to any preceding claim for use in the treatment of a disease or disorder.

### Claim 13

Use of a nucleic acid or conjugated nucleic acid or composition according to any preceding claim in the manufacture of a medicament for treating a disease or disorder.

### Claim 14

A method of treating a disease or disorder comprising administration of a nucleic acid or composition comprising a nucleic acid or conjugated nucleic acid according to any one preceding claim to an individual in need of treatment.

### Claim 15 (depends on 3, 13, 14)

Use or method according to any of claims 13-14, or a nucleic acid for use according to claim 3, wherein said disease or disorder is selected from the group comprising hemochromatosis, erythropoietic porphyria, transfusional iron overload and blood disorders.

### Claim 16 (depends on 12, 13, 14, 15)

A nucleic acid for use according to claim 12, use according to claim 13 or 15 or a method according to claim 14 or 15, wherein the nucleic acid is for one or more or all of:
(i) treatment of anemia, optionally suitably determined by an increase in haemoglobin; and/or
(ii) amelioration of splenomegaly, optionally determined by a reduction of spleen size or weight: and/or
(iii) reduction of stressed erythropoiesis in spleen, optionally determined by the proportion of erythroblasts and enucleated erythroid cells determined by FACS analysis, as described herein; and/or
(iv) improvement of red blood cell maturation/erythropoiesis in the bone marrow, optionally determined by the proportion of erythroblasts and enucleated erythroid cells determined by FACS analysis.
